Drug-drug interaction study to assess the effects of atorvastatin co-administration on pharmacokinetics and anti-thrombotic properties of cilostazol in male Wistar rats

BITS-Pilani Hyderabad Campus, Pharmacy Department, Hyderabad Campus, Hyderabad, Andhra Pradesh, India. .
Biopharmaceutics & Drug Disposition (Impact Factor: 2.34). 11/2012; 33(8):455-65. DOI: 10.1002/bdd.1812
Source: PubMed


Cilostazol (CLZ) and atorvastatin (ATV) are often co-prescribed to treat conditions such as peripheral arterial disease. In the present study, the drug-drug interaction potential of multi-dose ATV co-administration with CLZ on both pharmacokinetics and the anti-thrombotic property of CLZ is demonstrated. The pharmacokinetic parameters of CLZ (6 mg/kg, twice daily) were determined in male Wistar rats after 7 days co-administration with ATV (5 mg/kg, once daily) in order to assess the interaction potential between CLZ and ATV on chronic treatment. In vitro metabolic inhibition and everted gut sac studies were conducted to elucidate the mechanism of this interaction. Pharmacodynamic drug-drug interaction was evaluated on anti-thrombotic models including time to occlusion, platelet aggregation and rat tail bleeding time. A validated LC-MS/MS method was employed simultaneously to quantify both ATV and CLZ in rat plasma matrix. A statistically significant increase in systemic exposure (Css(max) by ~1.75 fold; AUC by ~3.0 fold) to CLZ was observed in ATV pre-treated rats. In vitro metabolism studies using liver microsomes (RLM and HLM) demonstrated statistically significant inhibition of CLZ metabolism when co-incubated with ATV. No change in apparent permeability of CLZ was observed in the presence of ATV. Atorvastatin showed a significant delay in artery occlusion time without altering CLZ's bleeding time and platelet aggregation profile. Collectively the results of these studies provide metabolic insight into the nature of drug-drug interaction between the selected drugs. Co-administration with ATV influences the pharmacokinetics and anti-thrombotic property of CLZ. A thorough clinical investigation is required before extrapolation of data to humans. Copyright © 2012 John Wiley & Sons, Ltd.

Download full-text


Available from: Rahul Vats, Feb 21, 2014
41 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Shortening tuberculosis treatment could significantly improve patient adherence and decrease the development of drug resistance. Phosphodiesterase inhibitors (PDE-Is) have been shown to be beneficial in animal models of tuberculosis. We assessed the impact of PDE-Is on the duration of treatment in tuberculous mice. Methods: We analyzed the time to death in Mycobacterium tuberculosis-infected mice receiving type 4 PDE-Is (rolipram and cilomilast) and the impact on bacterial burden, time to clearance, and relapse when types 3 and 5 PDE-Is (cilostazol and sildenafil, respectively) and rolipram were added to the standard treatment. We investigated pharmacokinetic interactions between PDE-Is (cilostazol and sildenafil) and rifampin. Results: The type 4 PDE-Is rolipram and cilomilast accelerated the time to death in tuberculous mice. The addition of rolipram to standard tuberculosis treatment increased bacterial burden and did not decrease the time to bacterial clearance in the lung, while the addition of the cilostazol and sildenafil reduced the time to clearance by 1 month. Cilostazol and sildenafil did not have negative pharmacokinetic interactions with rifampin. Conclusions: Type 4 PDE-Is may increase the severity of tuberculosis and should be carefully investigated for use in patients with latent or active tuberculosis. Cilostazol and sildenafil may benefit tuberculosis patients by shortening the duration of therapy.
    The Journal of Infectious Diseases 05/2013; 208(3). DOI:10.1093/infdis/jit187 · 6.00 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to evaluate transporter-mediated renal excretion mechanism for cilostazol and to characterize the mechanism of drug-drug interaction (DDI) between cilostazol and aspirin or probenecid. Concentrations of cilostazol and its metabolites (OPC-13015 and OPC-13213) in rat biological or cell samples were measured by LC-MS/MS. Co-administration with probenecid, benzylpenicillin or aspirin decreased cilostazol cumulative urinary excretion and renal clearance. Concentrations of cilostazol and OPC-13213 in plasma were decreased and OPC-13015 concentration was increased in presence of probenecid, whereas, in combination with benzylpenicillin or aspirin, rat plasma cilostazol sharply increased and concentrations of OPC-13015 and OPC-13213 did not change. In urine, OPC-13015 was below the level of detection. Cumulative urinary excretion of OPC-13213 decreased in presence of probenecid, benzylpenicillin or aspirin. Cilostazol was distributed in kidney and liver with Kp values of 8.4 mL/g and 16.3 mL/g. Probenecid and aspirin reduced cilostazol distribution in kidney. Probenecid did not affect cilostazol metabolism in kidney, but increased cilostazol metabolism in liver, and aspirin had no effect on cilostazol metabolism. Benzylpenicillin, aspirin and JBP485 reduced cilostazol uptake in kidney slices and hOAT3-HEK293 cells, while -aminohippuric acid did not. Compared to vector, hOAT3-HEK293 cells accumulated more cilostazol whereas hOAT1-HEK293 cells did not. OAT3 and Oat3 play the major role in cilostazol renal excretion, while OAT1 and Oat1 do not. Oat3 and Cyp3a are both targets of DDI between cilostazol and probenecid. Aspirin inhibits OAT3-mediated uptake of cilostazol and does not influence cilostazol metabolism.
    Drug metabolism and disposition: the biological fate of chemicals 04/2014; 42(6). DOI:10.1124/dmd.113.055194 · 3.25 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A cocktail approach can detect the activities of multiple cytochrome P450 (CYP) isoforms following the administration of multiple CYP-specific substrates in a single experiment. In this study, we aimed to develop a simultaneous and comprehensive in vivo analysis of CYP activity in rats. Rats received oral administration of losartan (10 mg/kg) and omeprazole (40 mg/kg). Caffeine (1 mg/kg), dextromethorphan (10 mg/kg), and midazolam (10 mg/kg) were administered 15 min later. In the drug-interaction phase, the rats were orally treated with dexamethasone (80 mg/kg) 24 h before, or with ketoconazole (10 mg/kg), fluvoxamine (100 mg kg), or fluconazole (10 mg/kg) 1 h before, the administration of cocktail drugs. The concentrations of the drugs and their metabolites were determined by LC/MS/MS. Plasma concentrations of 5 CYP substrates and their metabolites were simultaneously evaluated after the oral drug administration. Fluvoxamine and fluconazole significantly increased Cmax and AUC of caffeine, and AUC of omeprazole and midazolam. Dexamethasone significantly increased Cmax and AUC of losartan, while it decreased Cmax of midazolam. Ketoconazole showed no significant effect on the pharmacokinetic parameters of the tested drugs. In conclusion, a cocktail approach was developed for simultaneous and comprehensive analysis of the activities of multiple CYP isoforms in rats. In this approach, the effects of inhibitors and an inducer of various CYP isoforms were examined. Although further studies are necessary to predict effects in humans, this approach may be expected to serve as a convenient method for detecting drug-drug interactions in rats. This article is protected by copyright. All rights reserved.
    Biopharmaceutics & Drug Disposition 05/2014; 35(4). DOI:10.1002/bdd.1888 · 2.34 Impact Factor